Allievex Corp.

→ Revance feels like it has a competitive advantage over AbbVie ’s blockbuster Botox with only biannual injections of its freshly approved Daxxify , as opposed to the injections every three or four months that Botox requires. But you come at the king, you best not miss, and as Daxxify hits the market, Revance has now tapped David Hollander as CMO. Hollander was previously the chief R&D officer at Aerie Pharmaceuticals , which was sold to Alcon a couple months ago in a $770 million deal , and he has familiarity with the Botox developer through his 10 years at Allergan . From 2011-16, he was Allergan’s VP, global therapeutic area head in clinical development for anterior segment and consumer eye care. The Nashville biotech is also testing DaxibotulinumtoxinA in patients with cervical dystonia, among other conditions. → Now under the leadership of ex- Intercept CEO Mark Pruzanski and part of this year’s Endpoints 11 class , obesity startup Versanis Bio has welcomed Kenneth Attie as CMO and Aditya Venugopal as SVP, corporate development and strategic planning. Attie was one of the staffers left out in the cold at Imara as it whittled down to a six-person company in April but turned around its fortunes by reverse merging with Enliven Therapeutics last week. Before he was Imara’s medical chief, Attie spent 11 years at Acceleron as VP, medical research. In a mini-reunion, Venugopal worked for Pruzanski at Intercept as head of strategic planning, and since 2020 he had been VP of business development for Luca Santarelli at VectivBio . → Wholesale changes are being made at Scynexis , and not just with a slimmed-down pipeline as it shops around for a commercialization partner with Brexafemme . CEO Marco Taglietti will retire on Dec. 31, setting up CMO David Angulo to replace him as we ring in 2023. Ex- Eisai and Athersys finance chief Ivor Macleod ’s first day as CFO will be Oct. 24, while chief commercial officer Christine Coyne ’s job has been phased out. Scynexis will also be making more cuts to a staff that stood at 56 employees as of March 1, but the exact number wasn’t revealed. Kyle LaHucik has more on a company in flux . → Lyn Baranowski has taken over for Bruce Montgomery as CEO of Seattle-based pulmonary disease outfit Avalyn Pharma , once known as Genoa Pharmaceuticals . Since 2018, Baranowski knows the pulmonary space well from her four years as operations chief at Altavant , and from 2013-18, the Novartis alum was SVP of corporate development & strategy with Melinta Therapeutics . Avalyn’s lead program is an inhaled version of pirfenidone named AP01 for idiopathic pulmonary fibrosis. → The CEO situation has taken a turn at Maravai LifeSciences , where former Danaher SVP Trey Martin had succeeded Carl Hull earlier this month — or so we thought. Three Danaher subsidiaries have a bone to pick with the appointment, suing Martin and Maravai , and “alleging that Martin is in breach of a noncompetition agreement.” With a temporary restraining order in place, Hull didn’t hide his displeasure as he retakes his old position. “We have complete confidence in Trey and are appalled that Danaher would seek to leverage a noncompetition agreement to prevent Trey from advancing his career,” Hull said in a statement. → Alice Zhang ’s AI drug discovery shop Verge Genomics has installed 14-year Biogen vet John Applegate as CFO. Formerly the VP of finance & accounting with Valo Health , Applegate closed out his Biogen career in 2019 as head of R&D finance. Zhang just contributed to Ochre Bio ’s $30 million Series A , while Verge’s latest round of funding totaled $98 million in December 2021 . In another Biogen connection, ex-R&D chief and current Voyager CEO Al Sandrock joined the board of directors at Verge in February. → Zentalis Pharmaceuticals has been relentless with its leadership moves since the Kim Blackwell era began in May with a $200 million cash infusion , promoting co-founders Cam Gallagher and Kevin Bunker while picking up a CMO and general counsel in that span. This week Zentalis returns to Peer Review with Mark Lackner as chief translational officer, head of biomarker strategy. Before he was head of biology and translational sciences for Ideaya Biosciences , Lackner led the oncology early-stage biomarker group as part of his 13 years at Genentech . → Co-founded and chaired by Tillman Gerngross , oncology outfit Ankyra Therapeutics has recruited Joseph Elassal as CMO. Elassal has two stints at Regeneron on his résumé: one from 2012-18, and the other as senior medical director, global medical affairs, oncology since 2020. In between, he was a deputy VP at PhRMA and a senior medical director for Replimune . Ankyra bagged a $45 million Series B in November 2021 with the help of Polaris , GV and a number of other investors. → Another Gerngross company, Invivyd , came out swinging when it was known as Adagio , with big aspirations for its Covid-19 monoclonal antibody along with bigger bucks. But the drug struck out against Omicron , and Gerngross was gone as CEO within a couple months. The name changed to Invivyd a few weeks ago, but the unease remains the same, as CFO/CBO Jane Henderson and chief commercial officer Eric Kimble have packed their bags. Fred Driscoll , a CFO with Renovacor , Flexion Therapeutics and Novavax , will bridge the gap as interim finance chief as Invivyd also says goodbye to an unspecified number of staffers. → Pittsburgh’s NeuBase Therapeutics has also been beset by layoffs, dismissing 60% of its employees this week while pivoting to gene editing. Sandra Rojas-Caro , NeuBase’s CMO since May 2021 who also began another role as head of R&D this past April, handed in her resignation. → As George Church ’s Colossal Biosciences continues its quest to bring back the woolly mammoth, its computational biology spinout Form Bio has locked in Mark Swendsen as chief revenue officer. Swendsen held the same position at DNAnexus before coming to Form Bio, which christened the boat with a $30 million Series A round in late September. → Flagship ’s Alltrna has dipped into the talent pool of the incubator’s most famous creation to find its VP, discovery platform. Caroline Köhrer comes to the tRNA player after more than two years as Moderna ’s director of RNA science — a key cog in the development of its Covid-19 vaccine — and five years overall. Alltrna chief Michelle Werner was part of Flagship’s rapid-fire CEO-partner appointments in April that included Margo Georgiadis and former AbbVie president Michael Severino . → While we have Flagship companies on our mind, Senda Biosciences has pulled in two new execs with the appointments of Lori Rudolph-Owen as COO and Barbara Bispham as general counsel. Rudolph-Owen hails from Goldfinch Bio , where she most recently served as chief development officer. Prior to that, Rudolph-Owen held a number of roles at Pfizer , AMAG Pharmaceuticals , MGI Pharma , Vertex and Millennium Pharmaceuticals . Bispham joins Senda from BridgeBio , where she was VP, head of legal. Prior to that, Bispham was with Goodwin Procter , Cooley and Reed Smith . → Not to be confused with the great basketball Hall of Famer Bob Pettit , Robert Petit has become the head of early clinical development at Orionis Biosciences , a cancer biotech that racked up $55 million in financing this week. Petit chairs the scientific advisory board and is the ex-CSO of Advaxis , which happened to make news the same day as Orionis’ raise by merging with Ayala Pharmaceuticals . One more thing about Orionis: Cormorant Asset Management founder and chief executive Bihua Chen is now a member of the board. → Nigel Horscroft has settled in as CSO of German antiviral biotech Atriva Therapeutics , replacing current scientific advisory board chairman Oliver Planz . Horscroft brings Big Pharma credentials with him from Pfizer, and during his time at CureVac from 2012-20, he was promoted to area head, molecular therapy. Atriva has also picked up two other clinical execs this year: Stephan Witte (VP, clinical science and operations) in January and Tim Overend (VP, clinical development and regulatory) in July. → Staying in Germany, Boehringer Ingelheim and GSK alum Thomas Bogenrieder has joined adenovirus-based cancer biotech Abalos Therapeutics as CMO. Bogenrieder had held the role of chief clinical officer at Swiss-based AMAL Therapeutics since July 2020 and is the ex-medical chief of Evaxion Biotech . A year ago around this time, Abalos topped off its Series A with $37.6 million in additional funding . → In September 2021, we told you about Roche vet Anja Harmeier taking the CEO job at Belgian remyelination biotech Rewind Therapeutics . Fast forward to this week, where Rewind has selected Irene Knuesel as CSO. Knuesel has Roche ties herself, closing out her six-year tenure in 2019 as the pharma giant’s head of the neuroimmunology and neurodegeneration section. Incidentally, Roche is under the microscope again in the Alzheimer’s space as we await data for its resuscitated drug gantenerumab . → Targeting solid tumors, Immuneering — one of many biotechs that took the Nasdaq plunge at the zenith of IPOs in 2021 — has brought in Leah Neufeld as chief people officer. Neufeld has worked in human resources for companies of all sizes, with J&J , Daiichi Sankyo and Prevail packing her résumé. The one-time head of HR at Intercept was recently the chief human resources officer for Jiangsu Hengrui subsidiary Luzsana Biotechnology . → Ashvattha Therapeutics , a hydroxyl dendrimer (HD) biotech based in the Bay Area, has pegged Steve Maricich as CMO. Maricich recently held the CMO post at Scripps ’ Calibr , and he’s been the medical chief at Allievex , the developer of a drug for Sanfilippo syndrome type B that was once in BioMarin ’s hands. → Jessica Atkinson has been appointed CBO of ImmuneID , a biotech out of Stephen Elledge ’s lab at Harvard that’s zeroing in on antibodies with its AI platform, called aiSPIRE. Atkinson rose to VP, business development at Foundation Medicine in 2019 after Roche’s $2.4 billion takeover , and she just had a brief run as SVP, business development of Glympse Bio . → Plainly-named IO Biotech , a Nasdaq newcomer in 2021 that’s going after IDO and PD-L1 with its cancer drugs IO102 and IO103 , has enlisted Amy Sullivan as CFO. Sullivan had a seat at the negotiating table as chief strategy officer of Kiadis when it was purchased by Sanofi for $358 million. The ex-SVP of corporate affairs at Keryx Biopharmaceuticals was also VP, investor relations and corporate communications with AMAG Pharmaceuticals. → Belgian biotech Bioxodes is changing up the top exec seat with the appointment of Marc Dechamps as CEO. Dechamps takes over the reins from company founder Edmond Godfroid , who is transitioning into the roles of COO and CSO. Dechamps brings with him experience from his times at GSK and ViiV Healthcare to the new role. → San Diego RNA editing biotech ADARx Pharmaceuticals is a busy bee in Peer Review too, naming Feriandas Greblikas as VP of clinical development after hiring CFO Chris Prentiss and CMC VP Christopher Claeboe this year. A veteran of Novo Nordisk , Biogen and Baxter , Greblikas comes to ADARx from Travere Therapeutics , where he was a senior medical director and clinical development lead. And in a previous gig, he worked for JJ Bienaimé as BioMarin’s medical director of phenylketonuria clinical trials. → Coming up on a year since its $60 million Series A , STAT3- and STAT6-focused Recludix Pharma is back in Peer Review with Paul Smith as SVP of biology. Smith, the ex-global research lead for Gilenya with Novartis, has also been senior director of inflammation and autoimmunity at Incyte . He held the role of VP, discovery biology at Connect Biopharma before pivoting to Recludix, a company out of San Diego that introduced CBO Matthew Caldemeyer in late September. → Transpacific oncology biotech AnHeart Therapeutics , which secured a $61 million Series B round last year, has welcomed aboard Heinrich Farin as senior medical director, clinical research and Michael Humphries as VP, head of US medical affairs. Farin hails from Mirati , where he served as senior medical director and has a prior stint as global senior medical director, clinical research and development at BeiGene . Earlier in his career, Farin had roles at Ariad Pharmaceuticals and Baxalta . Meanwhile, Humphries brings expertise from his time at Takeda Oncology , where he served as senior scientific director of global medical affairs. Prior to Takeda , Humphries had gigs at Bayer Healthcare Pharmaceuticals and Array Biopharma . → Swiss LILRB (leukocyte immunoglobulin-like receptor subfamily B) biotech ImmunOs Therapeutics has pegged Hilmar Ebersbach as VP, antibody development and protein engineering. Ebersbach had spent the last 15 years in biotherapeutic engineering and gene therapy at the Novartis Institutes for BioMedical Research . → Believe it or not, Daniel Ripley has ventured off to HighTide Therapeutics as SVP, business development. Ripley is an Ionis BD vet who led global business development for the last two years at Alpha Biopharma , and as the brave souls of HighTide give NASH a whirl with its lead program HTD1801 , he also has experience in the space as SVP of business development, program and alliance management at Conatus Pharmaceuticals , a Novartis partner plagued by NASH failures that merged with Histogen in 2020. → GSK India has named Bhushan Akshikar as managing director, succeeding Sridhar Venkatesh , who is transitioning to a senior role within the GSK Group. Akshikar joined GSK India in September 2011. Prior to GSK, Akshikar had a 15-year stint at J&J’s Janssen . → Ex-AMAG Pharmaceuticals CEO Brian Pereira has been named chairman at KalVista following the resignation of Martin Edwards and a resounding trial failure. Earlier this month, KalVista had to stop a Phase II trial of its hereditary angioedema drug KVD824 after issues with liver enzymes were detected throughout all three treatment groups. Pereira has been president and CEO of Otsuka sub Visterra since 2013. → Proteomics biotech SomaLogic , which reverse-merged onto Nasdaq with Eli Casdin’s SPAC with a $1.2 billion valuation last April, has tapped Troy Cox as executive chair of the board of directors, taking over from Chuck Lillis , who will remain on the board. Cox formerly served as president and CEO of Foundation Medicine and was SVP and officer at Genentech and held roles at UCB , Sanofi-Aventis and Schering-Plough . → Rocket Pharmaceuticals chief Gaurav Shah is now chairman of the board at Swiss gene therapy developer Anjarium Biosciences , which unveiled a $61 million launch round in September 2021 thanks to such big-name investors as Pfizer and Abingworth . And after joining the board at Oncorus in June, ex- Dicerna CEO Doug Fambrough also has a place in Anjarium’s boardroom. → Cell processing shop Curate Biosciences has reserved space for Shah’s chief technical officer at Rocket, Mayo Pujols , on the board of directors. Pujols was in charge of global manufacturing for liso-cel (now Breyanzi ) as Celgene ’s VP of global CAR-T operations and technology. → Belgian infectious disease biotech ExeVir has appointed Jeanne Bolger to chair the board of directors. After 13 years at GSK, Bolger switched to another pharma giant as VP of scientific licensing at J&J, later becoming the VP of venture investing at Johnson & Johnson Innovation (JJDC) . → Theseus Pharmaceuticals — a TKI player from OrbiMed whose stock $THRX recently hit its nadir practically a year to the day that it joined Nasdaq in a none-too-shocking development in this market — has added Incyte CMO Steven Stein to the board of directors. Stein is a former clinical development exec with GSK and Novartis Oncology . → Geron ’s EVP, corporate strategy and chief commercial officer Anil Kapur is making his way to the board of directors at Verastem Oncology . Kapur is the former head of early assets, biomarkers and external innovation for worldwide oncology commercialization for Bristol Myers Squibb and the ex-CCO at Actinium . → China-based Hangzhou Qihan Biotech has brought on Tony Ho to its board of directors. Ho joins after a four-year stint at CRISPR Therapeutics , where he most recently served as EVP and head of research & development. Ho’s prior experience includes roles as SVP and head of oncology integration and innovation at AstraZeneca , head of neurology and ophthalmology at Merck and co-founder and CSO at Neuronyx . → Following a recent Series C financing round, Inversago Pharma has reeled in Ed Mathers and Nanna Lüneborg to its board of directors. Mathers is a general partner at New Enterprise Associates and has previously served as EVP, corporate development and venture at MedImmune . Mathers currently serves as a director to a host of companies, including Rhythm Pharmaceuticals , Synlogic , Senti Bio , Inozyme , Akouos and Affinia . Meanwhile, Lüneborg is a general partner at Forbion and formerly served a decade-long stint as a partner at Novo Ventures . → The Illinois Biotechnology Innovation Organization ( iBIO ) has added three new faces to its board of directors with the appointments of: Rahul Jerath (senior director, head of oncology business development & acquisitions at AbbVie), Phil Tennant (SVP and head of oncology business unit at Astellas ), and Joe Whalen (SVP, alliances & international business development at Horizon Therapeutics ). Illustration: Kim Ryu for Endpoints News

With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership position as Q3 comes to a close. Maravai Life Sciences Carl Hull has been reinstated as chief executive officer of San Diego-based Maravai Life Sciences on an interim basis after William “Trey” Martin, III, who was appointed CEO of Maravai earlier this month, became the subject of a lawsuit. Companies where Martin III previously served alleged he was in breach of a noncompetition agreement. On Oct 18, the Delaware Court of Chancery issued a temporary restraining order against Martin, prohibiting him from working for Maravai pending a preliminary injunction hearing. That hearing is expected to be held later this year. Martin has been placed on paid leave pending the outcome of this matter, Maravai announced. Predictive Oncology Raymond F. Vennare will assume the role of CEO and chairman of the Minnesota-based Predictive Oncology's board of directors on Nov 1. He has served on the company’s board of directors since 2021. Since 2015, Vennare has served as CEO and Chairman of Cvergenx, Inc., a genomic informatics company. Vennare’s earlier experience includes co-founding ThermalTherapeutic Systems, Inc., where he served as president and CEO. He also served as president and CEO of ImmunoSite, Inc. Alzheimer’s Association Joanne Pike, who currently serves as president, will take over as CEO of the Alzheimer’s Association. Pike will succeed Harry Johns, who has served as the association’s CEO since 2005. Since joining the Alzheimer’s Association in 2016, Pike has held numerous responsibilities. She previously served as chief strategy officer of the association and chief program officer. Exagen Inc. John Aballi will succeed Ron Rocca as president and CEO of San Diego-based Exagen. Aballi has 15 years of diagnostic industry experience. Most recently, he served as senior vice president and general manager of urology and CLIA chief operations officer at Veracyte, Inc. Before that, Aballi was COO at Decipher Biosciences. Genuv, Inv. Korea’s Genuv named Jenny Choih as president of its newly-launched U.S. subsidiary. Choih, based in the Kendall Square section of Cambridge, will lead business development of GNUV205, the company’s newly unveiled multi-specific immuno-oncology drug candidate. TransCelerate Biopharma Inc. Janice Chung was promoted from chief operating officer to CEO. She will assume the new role on Jan. 1, 2023. Chang joined TransCelerate in 2014. She will succeed founding CEO Dalvir Gill, who announced his retirement after a career in drug development that spans over 30 years. Ashvattha Therapeutics Steve Maricich joined California-based Asvattha as chief medical officer. Maricich joins Ashvattha from Calibr and Scripps BioVentures, where he served as the CMO. His previous experience includes the CMO role at Allievex, a rare disease start-up company that he helped spin out of BioMarin Pharmaceuticals. Caris Life Sciences George W. Sledge Jr. was named CMO of Texas-based Caris Life Sciences. Sledge will have oversight for medical affairs, research, and medical education. Before joining Caris, Sledge was a professor of medicine at the Stanford University School of Medicine, where he served as a member of the oncology division. He was most recently co-director of the Stanford Cancer Institute’s Cancer Therapeutics Program and served as chief of the division of oncology. Sledge is the former president of the American Society of Clinical Oncology and, until recently, served as both the chief scientific advisor for the Susan G. Komen Foundation and member of the Triple Negative Breast Cancer Foundation scientific advisory board. Versanis Bio Kenneth Attie was named CMO of New York-based Versanis. Attie most recently was CMO at Imara Inc. Prior to his role at Imara, Attie served as vice president of medical research at Acceleron Pharma for more than a decade. He also held leadership roles at Altus Pharmaceuticals and Insmed and spent more than a decade at Genentech. Additionally, the company named Aditya Venugopal as SVP of corporate development and strategic planning. Most recently, Venugopal served as vice president of business development at VectivBio. Before joining VectivBio, he was head of strategic planning at Intercept Pharmaceuticals. Previously, he spent seven years in strategic life science consulting, first at Easton Associates and then at Navigant Consulting. Rewind Therapeutics Irene Kneusel was named chief scientific officer at Rewind Therapeutics. She is a founder of Scienza Consulting GmbH, an independent science consultancy company. She spent six years at Hoffmann-La Roche, most recently holding the position of head of the neuroimmunology and neurodegeneration section. Before F. Hoffman-La Roche, she held numerous academic positions in neurobiology at the University of Zurich, the California Institute of Technology and the Federal Institute of Technology in Switzerland. Alexion Scott Weintraub was named SVO and head of U.S. commercial operations for Alexion, the rare disease business unit of AstraZeneca. Weintraub first joined Alexion in 2019. For the past two years, Weintraub has been the head of global commercial strategy. Prior to that, he led the neurology and ophthalmology therapeutic areas. Before Alexion, Weintraub held roles at Concert Pharmaceuticals, Inc., FORUM Pharmaceuticals and AstraZeneca. ImmuneID Jessica Atkinson was named chief business officer. Atkinson joins ImmuneID from Glympse Bio., Inc., where she was the SVP of business development. Prior to Glympse, she managed an oncology therapeutics market-based business development strategy at Foundation Medicine, Inc. Foresite Labs Mary Helen Black was named head of genomics. Before joining Foresite Labs, Black was the head of population analytics and computational sciences at Janssen Pharmaceutical. Black was also previously a director and research scientist for Ambry Genetics and Kaiser Permanente. Evozyne Zach Serber was appointed chief operating officer of Chicago-based Evozyne. Serber was formerly the CSO and co-founder of Zymergen and director of biology at Amyris.

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer. Dr. Maricich joins Ashvattha as a seasoned clinical development physician and translational scientist with more than 15 years of industry and academic experience that includes working with small molecules, biologics, cell and gene therapies across multiple therapeutic areas including cancer, GI disease, hematology, neurology, and rare disease. “We are thrilled to welcome Dr. Maricich to our senior management team,” said Jeff Cleland, Ph.D., chairman and CEO of Ashvattha. “He joins at a pivotal time for the company as we prepare to initiate clinical trials of our neurology hydroxyl dendrimer candidates next year. His neurology background and expertise advancing preclinical programs to clinical development will be a major asset to our team and the growth of the company.” Dr. Maricich added, “I am excited to join Ashvattha, and I look forward to working with the team to unlock the full potential of the hydroxyl dendrimer platform. To date, attempts to deliver drugs to the brain via systemic administration have not translated to the clinic. I believe that HDTs represent a new precision medicine approach that transcends tissue barriers and possesses the ability to change the standard of care across a number of disease indications.” Dr. Maricich joins Ashvattha from Calibr and Scripps BioVentures, where he served as the chief medical officer. There, he oversaw the development of clinical-stage oncology and GI programs and designed clinical paths for preclinical programs across a wide range of indications. Dr. Maricich’s previous experience includes the CMO role at Allievex, a rare disease start-up company that he helped spin out of BioMarin Pharmaceuticals. Over the course of his career, Dr. Maricich has secured more than $2M in grant funding from the NIH and other privately operated organizations. Dr. Maricich earned his M.D. and Ph.D. degrees in neuroscience from Case Western Reserve University. He is a board-certified child neurologist with experience as a primary investigator while serving as pediatrics and child neurology faculty at Baylor College of Medicine/Texas Children’s Hospital, Case Western Reserve University/Rainbow Babies and Children’s Hospital, and the University of Pittsburgh/UPMC Children’s Hospital of Pittsburgh. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology. Hydroxyl dendrimers (HDs) are a targeted nanomedicine technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease-modifying drugs create novel proprietary HDTs selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: Media Contact Sky Striar LifeSci Communications 617-797-6672 sstriar@lifescicomms.com